Mesoblast to File Biologics License Application for Ryoncil-March 2024-www.financetom.com

Mesoblast to File Biologics License Application for Ryoncil

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Mesoblast to File Biologics License Application for Ryoncil

Jul 1, 2024 1:19 AM

03:48 AM EDT, 07/01/2024 (MT Newswires) -- Mesoblast (MESO) said Monday it would file a biologics license application with the US Food and Drug Administration next week for approval of Ryoncil, or remestemcel-L, to treat children with steroid-refractory acute graft versus host disease.

Price: 6.66, Change: -0.15, Percent Change: -2.20

Previous page： Mama's Creations Shares Rise Following Fiscal Q4 Earnings Result Next page： Electrolux CEO Jonas Samuelson to leave

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Mama's Creations Shares Rise Following Fiscal Q4 Earnings Result

Apr 25, 2024

02:10 PM EDT, 04/25/2024 (MT Newswires) -- Mama's Creations (MAMA) shares were up 10.3% in recent Thursday trading following the company's fiscal Q4 earnings late Wednesday. The company booked fiscal Q4 diluted earnings of $0.04 per share, down from $0.06 per share a year earlier. Analysts polled by Capital IQ expected $0.03. Revenue for the quarter ended Jan. 31 was...

Electrolux CEO Jonas Samuelson to leave

Apr 25, 2024

(Reuters) - Electrolux , the world's second-biggest appliances maker, said on Thursday its chief executive Jonas Samuelson would leave his position on Jan. 1, 2025. ...

Valley National, Eagle Bancorp latest to disclose earnings hit due to CRE footprint

Apr 25, 2024

April 25 (Reuters) - Valley National Bancorp ( VLY ) and Eagle Bancorp ( EGBN ) were the latest regional banks to outline a hit to their earnings from exposure to commercial real estate (CRE) loans, underscoring the uncertainty that has clouded the industry. High interest rates and borrowing costs have heightened worries of debt defaults in the CRE market,...

Inter Parfums Shares Decline After Q1 Net Sales Fall Short of Consensus

Apr 25, 2024

02:12 PM EDT, 04/25/2024 (MT Newswires) -- Inter Parfums ( IPAR ) shares were down nearly 9% in recent trading Thursday, a day after it reported Q1 net sales of $324 million that were up from $312 million a year earlier, but missed the consensus polled by Capital IQ of $334.2 million. European-based operations net sales remained nearly flat year...